IGM Biosciences Ends Genzyme Collaboration, Cuts Workforce

IGM Biosciences ( (IGMS) ) just unveiled an update.

On May 5, 2025, IGM Biosciences announced the termination of its Collaboration and License Agreement with Genzyme Corporation, effective 30 days from notice. As a result, IGM Biosciences is reducing its workforce by approximately 80% and closing most of its lab and office facilities to conserve cash, while exploring strategic alternatives and reorganization options.

Spark’s Take on IGMS Stock

According to Spark, TipRanks’ AI Analyst, IGMS is a Underperform.

IGM Biosciences faces significant financial challenges with high R&D costs leading to persistent losses and negative equity. Although revenue is growing, it’s insufficient for profitability, necessitating ongoing external funding. Technically, the stock shows potential stabilization signals, but substantial risks remain due to its weak financial position and negative valuation metrics.

To see Spark’s full report on IGMS stock, click here.

More about IGM Biosciences

IGM Biosciences, Inc. operates in the biotechnology industry, focusing on the development and commercialization of IgM antibodies targeting oncology and immunology.

Average Trading Volume: 195,131

Technical Sentiment Signal: Sell

Current Market Cap: $69.94M

Find detailed analytics on IGMS stock on TipRanks’ Stock Analysis page.